GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » Gross Profit

KRRO (Korro Bio) Gross Profit : $2.27 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio Gross Profit?

Korro Bio's gross profit for the three months ended in Dec. 2024 was $2.27 Mil. Korro Bio's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $2.27 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Korro Bio's gross profit for the three months ended in Dec. 2024 was $2.27 Mil. Korro Bio's Revenue for the three months ended in Dec. 2024 was $2.27 Mil. Therefore, Korro Bio's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

Korro Bio had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Korro Bio Gross Profit Historical Data

The historical data trend for Korro Bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio Gross Profit Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Gross Profit
- - - 2.27

Korro Bio Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - 2.27

Competitive Comparison of Korro Bio's Gross Profit

For the Biotechnology subindustry, Korro Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where Korro Bio's Gross Profit falls into.



Korro Bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Korro Bio's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=2.271 - 0
=2.27

Korro Bio's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=2.271 - 0
=2.27

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.27 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Korro Bio's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.27 / 2.271
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Korro Bio  (NAS:KRRO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Korro Bio had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Korro Bio Gross Profit Related Terms

Thank you for viewing the detailed overview of Korro Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio Business Description

Traded in Other Exchanges
N/A
Address
60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
Vineet Agarwal officer: Chief Financial Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139